Gastric Cancer Breakthrough: Young Patient Achieves Complete Remission with Targeted Therapy and Surgery

Strategic Insights -

A breakthrough in gastric cancer treatment has been reported by researchers at Nanjing Medical University in Jiangsu, People's Republic of China. A 35-year-old female patient with recurrent and metastatic gastric cancer, who had previously failed multiple therapies, including chemotherapy and immunotherapy, achieved complete remission after undergoing a novel treatment combining CLDN18.2-targeted antibody-drug conjugate therapy (LM302) and surgery to remove ovarian metastases.

Key Takeaways:

  • The patient, a 35-year-old female, had recurrent and metastatic gastric cancer that had resisted chemotherapy and immunotherapy.
  • The patient's cancer had spread to bilateral ovaries and lymph nodes, with multiple treatments having failed.
  • The patient was enrolled in a Phase I/II trial of LM302, a CLDN18.2-targeted antibody-drug conjugate, and underwent eight cycles of treatment.
  • Imaging showed significant regression of lymph node lesions and stable ovarian metastases after treatment.
  • In April 2024, the patient underwent laparoscopic resection of the ovarian tumors, which were confirmed to have no residual disease upon pathology.
  • As of March 2025, the patient remains disease-free with excellent performance status, illustrating the potential of biomarker-driven precision medicine in treating refractory gastric cancer.

Statistics:

  • The patient's cancer had progressed to bilateral ovarian metastases, involving both ovaries and lymph nodes.
  • The patient received eight cycles of LM302 treatment as part of a Phase I/II clinical trial.
  • Imaging studies showed significant regression of lymph node lesions and stable ovarian metastases after treatment.
  • The patient underwent laparoscopic resection of the ovarian tumors in April 2024, with no residual disease confirmed upon pathology.
  • As of March 2025, the patient had remained disease-free for over ten months, with excellent performance status.

Sources:

  • Complete remission of recurrent gastric cancer in a young female patient through CLDN18.2-targeted therapy (LM302) and metastatic ovarian tumor resection: a case report of refractory disease overcoming chemotherapy and immunotherapy resistance. Frontiers in Oncology, 2025,15.
  • OBGYN & Reproduction Week. September 1, 2025; p 413.